Analysts estimate that Kymera Therapeutics will report an earnings per share (EPS) of $-0.84.
The market awaits Kymera Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Performance in Previous Earnings
The company's EPS beat by $0.10 in the last quarter, leading to a 4.22% increase in the share price on the following day.
Here's a look at Kymera Therapeutics's past performance and the resulting price change:
Quarter
Q2 2024
Q1 2024
Q4 2023
Q3 2023
EPS Estimate
-0.68
-0.73
-0.40
-0.72
EPS Actual
-0.58
-0.69
-0.25
-0.90
Price Change %
4.0%
3.0%
3.0%
18.0%
Analyst Opinions on Kymera Therapeutics
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Kymera Therapeutics.
With 5 analyst ratings, Kymera Therapeutics has a consensus rating of Outperform. The average one-year price target is $52.8, indicating a potential 8.89% upside.
Peer Ratings Comparison
In this comparison, we explore the analyst ratings and average 1-year price targets of Iovance Biotherapeutics, Apellis Pharmaceuticals and Amicus Therapeutics, three prominent industry players, offering insights into their relative performance expectations and market positioning.
The consensus among analysts is an ...